Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it will report preclinical advances with its antibody-drug conjugate (ADC) technology during the 2005 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held November 14-18, 2005 at the Pennsylvania Convention Center in Philadelphia. In addition, two of Seattle Genetics’ collaborators, CuraGen and MedImmune, will make presentations regarding their ADC programs utilizing Seattle Genetics’ technology.
